Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could pausing psychiatric pills boost PTSD therapy?

NCT ID NCT07802158

Disease control Sponsor: Academic Centre for Dentistry in Amsterdam Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study asks whether tapering and stopping certain psychotropic medications before intensive trauma-focused psychotherapy helps people with PTSD more than continuing those medications during therapy. Researchers will compare patients treated under a new medication-review policy, which discontinues drugs like amitriptyline and mirtazapine when prescribed off-label for PTSD symptoms, with similar patients from 2021-2024 who kept taking the same drugs. The main question is whether stopping these medications leads to a greater reduction in PTSD symptoms after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tapering and discontinuing selected psychotropic medications (amitriptyline, mirtazapine, quetiapine, topiramate, zolpidem, zopiclone) before trauma-focused psychotherapy
What this could lead to
If stopping these medications before therapy helps, it could point to a simple way to make PTSD treatment more effective for many people.
What could go wrong
This is an observational comparison, not a randomized trial, so other factors could explain any differences. Tapering medications carries risks like withdrawal or worsening symptoms, and the policy only applies when doctors deem it safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chronic post-traumatic stress disorder

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pseudonymized data from patients treated at PSYTREC from late 2026 onwards (after the policy change) that gave written informed consent for the use of their data for research purposes Exclusion Criteria: * Patients who did not give written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post traumatic stress disorder PTSD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post traumatic stress disorder PTSD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.